EpiVario

Executive Summary

EpiVario is a privately held biotechnology company pioneering neuroepigenetic modulators to treat memory-related disorders, including substance use disorders and PTSD. Founded in 2017 and based in Boston, the company targets the metabolic enzyme ACSS2, a key regulator of epigenetic gene activation during memory formation and reconsolidation. By disrupting maladaptive memory processes, EpiVario's approach could offer a novel therapeutic strategy for conditions with high unmet need. The company is in the preclinical stage, with no disclosed pipeline details or total funding. Its innovative platform has potential to address the underlying mechanisms of addiction and trauma-related disorders, though significant clinical validation is still required. The company's progress will depend on advancing its lead candidates into IND-enabling studies and securing partnerships or funding to support development.

Upcoming Catalysts (preview)

• Q2 2027Announcement of Series A Financing50% success
• Q4 2027IND Filing for Lead Program30% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data70% success